EA201792286A1 - Способы лечения рака - Google Patents
Способы лечения ракаInfo
- Publication number
- EA201792286A1 EA201792286A1 EA201792286A EA201792286A EA201792286A1 EA 201792286 A1 EA201792286 A1 EA 201792286A1 EA 201792286 A EA201792286 A EA 201792286A EA 201792286 A EA201792286 A EA 201792286A EA 201792286 A1 EA201792286 A1 EA 201792286A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- treating cancer
- capox
- folfox
- regorafenib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Способы, включающие введение по меньшей мере одного соединения формулы (I)по меньшей мере одного дополнительного вида противораковой терапии, выбранного из панитумумаба, цетуксимаба, капецитабина, CAPOX, регорафениба и FOLFOX;и наборы, содержащие по меньшей мере одно соединение формулы (I)по меньшей мере один дополнительный вид противораковой терапии, выбранный из панитумумаба, цетуксимаба, капецитабина, CAPOX, регорафениба и FOLFOX.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562149349P | 2015-04-17 | 2015-04-17 | |
PCT/US2016/028179 WO2016168858A1 (en) | 2015-04-17 | 2016-04-18 | Methods for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201792286A1 true EA201792286A1 (ru) | 2018-03-30 |
Family
ID=55854800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792286A EA201792286A1 (ru) | 2015-04-17 | 2016-04-18 | Способы лечения рака |
Country Status (16)
Country | Link |
---|---|
US (1) | US20180098959A1 (ru) |
EP (1) | EP3283070A1 (ru) |
JP (1) | JP2018511642A (ru) |
KR (1) | KR20170137833A (ru) |
CN (1) | CN107820426A (ru) |
AU (1) | AU2016249158A1 (ru) |
BR (1) | BR112017022296A2 (ru) |
CA (1) | CA2983013A1 (ru) |
EA (1) | EA201792286A1 (ru) |
HK (1) | HK1250943A1 (ru) |
IL (1) | IL255016A0 (ru) |
MX (1) | MX2017013358A (ru) |
PH (1) | PH12017501881A1 (ru) |
SG (1) | SG11201708505WA (ru) |
TW (1) | TW201709905A (ru) |
WO (1) | WO2016168858A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
CN106211758B (zh) | 2013-04-09 | 2021-03-23 | 北京强新生物科技有限公司 | 2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途 |
WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2190429B1 (en) * | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
CN106211758B (zh) * | 2013-04-09 | 2021-03-23 | 北京强新生物科技有限公司 | 2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途 |
-
2016
- 2016-04-18 MX MX2017013358A patent/MX2017013358A/es unknown
- 2016-04-18 CA CA2983013A patent/CA2983013A1/en not_active Abandoned
- 2016-04-18 SG SG11201708505WA patent/SG11201708505WA/en unknown
- 2016-04-18 KR KR1020177032742A patent/KR20170137833A/ko unknown
- 2016-04-18 US US15/567,070 patent/US20180098959A1/en not_active Abandoned
- 2016-04-18 WO PCT/US2016/028179 patent/WO2016168858A1/en active Application Filing
- 2016-04-18 EP EP16723855.9A patent/EP3283070A1/en not_active Withdrawn
- 2016-04-18 CN CN201680032521.2A patent/CN107820426A/zh active Pending
- 2016-04-18 AU AU2016249158A patent/AU2016249158A1/en not_active Abandoned
- 2016-04-18 JP JP2017554375A patent/JP2018511642A/ja active Pending
- 2016-04-18 TW TW105112095A patent/TW201709905A/zh unknown
- 2016-04-18 BR BR112017022296A patent/BR112017022296A2/pt not_active Application Discontinuation
- 2016-04-18 EA EA201792286A patent/EA201792286A1/ru unknown
-
2017
- 2017-10-15 IL IL255016A patent/IL255016A0/en unknown
- 2017-10-18 PH PH12017501881A patent/PH12017501881A1/en unknown
-
2018
- 2018-08-14 HK HK18110437.0A patent/HK1250943A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016249158A1 (en) | 2017-11-02 |
US20180098959A1 (en) | 2018-04-12 |
EP3283070A1 (en) | 2018-02-21 |
WO2016168858A1 (en) | 2016-10-20 |
IL255016A0 (en) | 2017-12-31 |
TW201709905A (zh) | 2017-03-16 |
PH12017501881A1 (en) | 2018-03-05 |
CA2983013A1 (en) | 2016-10-20 |
KR20170137833A (ko) | 2017-12-13 |
JP2018511642A (ja) | 2018-04-26 |
SG11201708505WA (en) | 2017-11-29 |
MX2017013358A (es) | 2018-08-01 |
HK1250943A1 (zh) | 2019-01-18 |
CN107820426A (zh) | 2018-03-20 |
BR112017022296A2 (pt) | 2018-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
EA201892229A1 (ru) | Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
EA201290138A1 (ru) | Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция | |
EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
EA201590987A1 (ru) | Соединения и способы их применения | |
EA201290139A1 (ru) | Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких | |
EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
BR112017022323A2 (pt) | método para tratar doença do enxerto contra hospedeiro, uso de um composto, e, kit. | |
EA201792287A1 (ru) | Способы лечения рака | |
EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
EA201492187A1 (ru) | Способы лечения солидных опухолей с использованием кофермента q10 | |
PH12017501881A1 (en) | Methods for treating cancer | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer |